Older adults with HIV may safely switch to a simpler two-drug pill

NCT ID NCT05911360

Completed Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were followed for 48 weeks. The goal was to see if the simpler pill worked just as well at maintaining viral suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Phoenix, Arizona, 85015, United States
GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

Palm Springs, California, 92262, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20005, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Miami, Florida, 33133, United States
GSK Investigational Site

West Palm Beach, Florida, 33407, United States
GSK Investigational Site

Augusta, Georgia, 30912, United States
GSK Investigational Site

Decatur, Georgia, 30033, United States
GSK Investigational Site

Macon, Georgia, 31201, United States
GSK Investigational Site

Boston, Massachusetts, 02043, United States
GSK Investigational Site

Berkley, Michigan, 48072, United States
GSK Investigational Site

Detroit, Michigan, 48202, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

Omaha, Nebraska, 68198, United States
GSK Investigational Site

Las Vegas, Nevada, 89106, United States
GSK Investigational Site

The Bronx, New York, 10467, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Greensboro, North Carolina, 27401, United States
GSK Investigational Site

Wilmington, North Carolina, 28401-7684, United States
GSK Investigational Site

Akron, Ohio, 44304, United States
GSK Investigational Site

Portland, Oregon, 97239, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Innsbruck, 6020, Austria
GSK Investigational Site

Vienna, 1100, Austria
GSK Investigational Site

Brussels, 1200, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Toronto, Ontario, M5G 2N2, Canada
GSK Investigational Site

Montreal, Quebec, H2L 1N9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Nice, 6202, France
GSK Investigational Site

Orléans, 45100, France
GSK Investigational Site

Paris, 75004, France
GSK Investigational Site

Freiburg im Breisgau, 79106, Germany
GSK Investigational Site

Hanover, 30625, Germany
GSK Investigational Site

München, 80336, Germany
GSK Investigational Site

Milan, 20142, Italy
GSK Investigational Site

Modena, 41100, Italy
GSK Investigational Site

Roma, 161, Italy
GSK Investigational Site

Torino, 10149, Italy
GSK Investigational Site

Mérida, 97070, Mexico
GSK Investigational Site

Monterrey, 64460, Mexico
GSK Investigational Site

Amsterdam, 1105 AZ, Netherlands
GSK Investigational Site

Rotterdam, 3079 DZ, Netherlands
GSK Investigational Site

Utrecht, 3584 CX, Netherlands
GSK Investigational Site

Porto, 4099-001, Portugal
GSK Investigational Site

Porto, 4200-319, Portugal
GSK Investigational Site

Vila Nova de Gaia, 4434-502, Portugal
GSK Investigational Site

Manresa, Catalonia, 08243, Spain
GSK Investigational Site

Sabadell, Catalonia, 8208, Spain
GSK Investigational Site

Guadalajara, 19002, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Liverpool, L7 8XP, United Kingdom
GSK Investigational Site

London, SE1 9RT, United Kingdom
GSK Investigational Site

London, SW7 2AZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.